Production of interferon (IFN)-γ is critical for optimal antitumor immunotherapy in several preclinical animal models. Interleukin-12 (IL-12)-induced IFN−γ production is markedly defective after autologous stem cell transplantation. Quantitative deficiency in CD4 T cells, relative increase in CD25+ CD4+ T cells, and bias towards Th2 differentiation are not the primary mechanisms of defective IFN-γ production.
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Introduction
Non-Hodgkin's lymphoma is the most common of the hematologic malignancies 1 . The incidence of non-Hodgkin's lymphoma has been rising steadily for the past 50 years, and approximately 60,000 new cases are currently diagnosed annually in the United States. Because of this increased incidence, nonHodgkin's lymphoma is one of the few cancers for which mortality has increased in the past 20 years 2 .
High-dose therapy and autologous hematopoietic stem cell transplantation is the treatment of choice for eligible patients with non-Hodgkin's or Hodgkin's lymphoma that is refractory to or has relapsed after conventional chemotherapy [3] [4] [5] [6] . Nevertheless, more than 50 to 60% of patients with relapsed or refractory lymphoma will ultimately develop progressive disease after autologous stem cell transplantation. Novel strategies are needed to reduce the risk of recurrent lymphoma after high-dose therapy. One approach is post-transplant immunotherapy to eliminate chemotherapy-resistant tumor cells 7 . Immunotherapeutic approaches under investigation include post-transplant administration of monoclonal antibodies, immunostimulatory cytokines, and cancer vaccines [8] [9] [10] .
In attempts to stimulate effective antitumor immune responses, we have investigated the use of IL-12 after autologous stem cell transplantation. IL-12 plays an important role in the regulation of innate and adaptive immune responses 11 . In preclinical tumor models, IL-12 therapy induces regression of established primary tumors, inhibits the formation of distant metastases, and prolongs the survival of tumor-bearing mice [12] [13] [14] [15] . In several animal models production of IFN-γ in vivo has been shown to be necessary, but not sufficient, for the antitumor effects of IL-12 13, 14, 16, 17 . IL-12 mediates its immunologic effects by binding to a specific dimeric cell surface receptor complex, composed of β1 and β2 chains, which results in activation of the Janus kinases Jak2 and Tyk2 18, 19 . The subsequent activation of STAT4 is required for normal responses to IL-12 18, 20, 21 .
Our previous studies have shown that IL-12 can be safely given in biologically active doses after autologous stem cell transplantation 22 . However, serum IFN-γ levels during IL-12 therapy posttransplant were found to be an order of magnitude lower than those seen in non-transplant solid tumor patients receiving the same doses of IL-12 22, 23 . Moreover, post-transplant patient PBMCs were shown to be intrinsically defective in their ability to produce IFN-γ after direct in vitro stimulation with IL-12. We
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Methods
Patient and control subject samples
The study was approved by the Institutional Review Board at Indiana University Medical Center and written informed consent was obtained from each subject prior to collection of blood samples. Blood samples were obtained from patients with non-Hodgkin's and Hodgkin's lymphoma who were scheduled to undergo high-dose chemotherapy and autologous stem cell transplantation. Procedures for stem cell collection, administration of high-dose therapy, and autologous stem cell transplantation were as previously described 24 . Blood samples were obtained prior to collection of peripheral blood stem cells, prior to the initiation of high-dose chemotherapy, and after hematologic engraftment following autologous stem cell transplantation. Serum samples, obtained after allowing whole blood to clot at room temperature, were stored in aliquots at -70 o C. PBMCs were isolated on a Ficoll-diatrizoate gradient from venous blood samples. Control PBMCs were obtained from healthy volunteer donors. and control reagent SB202474 (4-ethyl-2-(p-methoxyphenyl)-5-(4-pyridyl)-1H-imidazole) were obtained from Calbiochem (San Diego, CA). Fluorochrome-conjugated monoclonal antibodies (mAb) specific for CD3 and CD4 were purchased from Beckman-Coulter (Brea, CA) and for CD56, IL-12R β1, IL-12R β2, IFN-γ, and tyrosine-phosphorylated STAT6 from BD PharMingen (San Diego, CA). MAb specific for STAT4 were obtained from BD Transduction Laboratories (Sand Diego, CA) and for GAPDH from Biodesign International (Saco, ME). Polyclonal rabbit antisera specific for STAT3 and Jak2 (Upstate, Lake Placid, NY), STAT4 and Tyk2 (Santa Cruz Biotechnology, Santa Cruz, CA), and tyrosine 25 , except that 15% fetal calf serum was substituted for 15% human AB serum.
Immunophenotypic analysis
PBMCs were stained directly with fluorochrome-conjugated mAb, washed, fixed in 1% formaldehyde, and analyzed by flow cytometry as previously described 25 
Cytokine levels
Patient and control PBMCs were thawed, washed in medium, and cultured at 50,000 or 250,000 cells per well in U-bottomed 96-well microplates in medium alone or medium containing stimuli as indicated. C, cell-free supernatants were collected and IFN-γ or IL-4 levels were measured using specific ELISA kits according to the manufacturer's instructions. Serum samples obtained from patients after autologous stem cell transplantation were thawed and IL-12 levels were measured using specific ELISA kits.
Immunoblotting
Patient and control PBMCs were thawed, washed in medium, and cultured in medium alone or medium containing cytokines as indicated. After stimulation, cells were washed with 10 mL of phosphate-buffered saline, lysed in 50 µL of protein lysis buffer as previously described 26 , followed by centrifugation at 12000 rpm at 4 o C for 5 minutes. Cleared total protein extracts (50 µg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred onto Nytran SuperCharge and Nytran N membranes (Schleicher & Schuell BioScience, Keene, NH). The blots were blocked in 3% dry non-fat milk in phosphate-buffered saline for 1 hour at room temperature, probed with rabbit polyclonal antibodies for 2 hours at room temperature, and subsequently incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:5000) for 1 hour at room temperature. The final reaction was developed with a Western Lightning Chemiluminescence Reagent Plus (PerkinElmer, Wellesley, MA). The blots were stripped and reprobed with polyclonal rabbit antisera or murine mAb recognizing STAT3, STAT4, Jak2, or Tyk2. A mAb to GAPDH was used as the loading control. For lysates of both control subject and patient PBMCs, immunoblots using the polyclonal antisera to STAT4 usually resulted in a large nonspecific band of faster electrophoretic mobility than the specific STAT4 band. Confirmation that the upper band represents authentic STAT4 was done by stripping and reprobing selected blots with a specific STAT4 mAb and by comparison with immunoblots using the polyclonal antisera to test lysates from cultured wild-type and STAT4-deficient murine lymphocytes.
Densitometric analysis of the STAT4 band was performed on immunoblots probed with the STAT4 mAb.
Polymerase chain reaction (PCR) analysis
Total RNA was extracted from PBMCs using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. One µg of total RNA was used for first strand cDNA
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 9 synthesis using the Cloned AMV First-Strand cDNA synthesis kit (Invitrogen). Seven µL of cDNA was used to amplify the STAT4 sequence by PCR as previously described 26 . The GAPDH sequence was amplified from 0.5 µL of cDNA using the sense primer 5'-ACCACAGTCCATGCCATCAC-3' and the antisense primer 5'-TCCACCACCCTGTTGCTGTA-3'. Five µL of amplified product was resolved on a 2.0% agarose gel stained with ethidium bromide. Intensity of the amplified bands was analyzed by densitometry.
Statistical analysis
The lower limit of detection for the IFN-γ ELISA is 8 pg/mL. For data analysis, samples with IFN-γ levels < 8 pg/mL were assigned a value of 8 pg/mL. Means, SE, and t-test comparisons were calculated using STATview software (Abacus Concepts, Piscataway, NJ). plated at 250,000 cells per well was less than 38 pg/mL for all but one of the 8 patients tested; it was an order of magnitude less than that detected in the supernatants of control subject PBMCs plated at 50,000 cells per well (data not shown).
Evaluation of CD25+ regulatory T cells after autologous stem cell transplantation
CD25+ regulatory T cells (T reg cells) are a subset of CD4 T cells that inhibit the activation and proliferation of conventional CD4 and CD8 T cells 30, 31 . CD25+ CD4+ T reg cells have been found to suppress IFN-γ production in vitro and IFN-γ -dependent antitumor immune responses in vivo 32, 33 .
Therefore, we examined whether CD25+ CD4+ T reg cells were relatively increased in PBMCs obtained from patients after autologous stem cell transplantation. The proportion of CD4 T cells that coexpressed CD25 in post-transplant patient PBMCs (30 + 8%) was not significantly different from the proportion (26 + 5%) in control subject PBMCs (P > 0.1). Moreover, because of the decreased absolute number of CD4 T cells post-transplantation, the absolute number of CD25+ CD4+ T cells in posttransplant patient PBMCs was significantly lower than that in control subject PBMCs (P < 0.005). PBMCs did not differ significantly (P > 0.1) from control subject PBMCs (data not shown).
Evaluation of Th1 and Th2 subsets after autologous stem cell transplantation
As the use of chemokine receptor expression to identify human Th1 and Th2 subsets is not uniformly accepted 40 , we also investigated the production of type 1 versus type 2 cytokines by PBMCs exposed to strong nonspecific stimulation in vitro. Control subject and patient PBMCs produced high levels of IFN-γ, but no detectable IL-4, under these experimental conditions (Table 1) (Table 2) . However, a significantly higher percentage of post-transplant patient NK cells expressed IL-12Rβ2 as compared to control subject NK cells (Table 2) .
For
Defective IL-12-induced STAT4 phosphorylation by post-transplant patient PBMCs
The data above indicate that the mechanism of defective IL-12-induced IFN-γ production by posttransplant PBMCs involves signaling events distal to the interaction of IL-12 with its cell surface receptor.
We therefore evaluated the integrity of IL-12 receptor-related signaling pathways in post-transplant patient PBMCs. Total cellular levels of Jak2 and Tyk2 were comparable in control subject and patient PBMCs (Figure 2) . Furthermore, as expected, IL-12 induced the tyrosine phosphorylation of STAT4 proteins in control subject PBMCs (Figure 3) . In contrast, STAT4 tyrosine phosphorylation was undetectable or barely detectable in post-transplant patient PBMCs incubated with IL-12. This defect in IL-12-induced STAT4 phosphorylation appears to be due to a deficiency in STAT4 protein levels in patient PBMCs as compared to control subject PBMCs (Figure 3) . By densitometric analysis, the relative amount of STAT4 protein in post-transplant patient PBMCs was 315 + 27 (mean + SE) as compared to 9720 + 1309 in control subject PBMCs (P = 0.02). In contrast, the levels of STAT3 protein were not significantly different comparing post-transplant patient to control subject PBMCs (Figure 2) . 
IL-12 levels in the serum of lymphoma patients after autologous stem cell transplantation
Prolonged exposure to IL-12 in vitro causes STAT4 protein levels to decline markedly in human NK cells and activated T cells 41, 42 . Given the enhanced expression of the IL-12 receptor complex on posttransplant patient PBMCs, high endogenous levels of IL-12 post-transplant could lead to internalization of IL-12 by PBMCs in vivo and subsequent STAT4 protein deficiency. We therefore measured serum IL-12 levels in 10 lymphoma patients after autologous stem cell transplantation. IL-12 was undetectable in the serum of 6 patients; IL-12 levels of 21, 30, 68, and 69 pg/mL were detected in the serum of 4 patients, 
Expression of STAT4 mRNA after autologous stem cell transplantation
Inhibition of STAT4 gene expression and/or mRNA stability could contribute to STAT4 protein deficiency post-transplant. We therefore evaluated STAT4 mRNA levels using the PCR technique. STAT4 mRNA levels were significantly lower in post-transplant as compared to control subject PBMCs, using GAPDH mRNA levels as a control for equal amounts of RNA ( Figure 5A ). Densitometric analysis confirmed that the ~69% reduction in STAT4 mRNA levels seen in post-transplant samples compared to control samples was statistically significant ( Figure 5B ).
IL-18 augments IL-12-induced IFN-γ production by post-transplant patient PBMCs
IL-18 can act synergistically with IL-12 to promote IFN-γ production by normal PBMCs. IL-18 by itself (in concentrations as high as 100 ng/mL) did not stimulate significant IFN-γ production by either control subject or patient PBMCs ( Figure 6 and data not shown). However, IL-12 and IL-18 in combination induced substantial IFN-γ production by both control and patient PBMCs. The level of IFN-γ secreted in response to IL-12 plus IL-18 was higher for control subject as compared to patient PBMCs ( Figure 6 ).
Nevertheless, patient PBMCs stimulated with IL-12 plus IL-18 produced IFN-γ in amounts that were not significantly different (P > 0.375) than those produced by control subject PBMCs stimulated with IL-12 alone. IFN-γ can also be detected in supernatants of post-transplant patient PBMCs incubated with IL-2 and IL-12 in combination 22 . However, IFN-γ levels (433 + 168 pg/mL) produced by post-transplant patient PBMCs stimulated with IL-12 plus 100 pM IL-2 were significantly less (P<0.025) than IFN-γ levels (>1000 pg/mL) produced by the same PBMCs stimulated with IL-12 plus 10 ng/mL IL-18.
Mechanism of augmented IFN-γ production by PBMCs stimulated with IL-12 and IL-18
As IL-12 plus IL-18 could restore IFN-γ production by post-transplant patient PBMCs, we examined whether IL-12 plus IL-18 could reverse defective STAT4 expression in these cells. In 4 samples tested, For personal use only. on September 24, 2017. by guest www.bloodjournal.org From we failed to detect increased STAT4 protein levels or cytokine-induced STAT4 tyrosine phosphorylation after incubation of post-transplant patient PBMCs with IL-12 plus IL-18 (data not shown). These results suggest that enhanced IFN-γ production under our experimental conditions occurs predominantly by mechanisms other than recovery of STAT4 protein levels. Activation of p38 MAPK has been reported to participate in both STAT4-dependent and STAT4-independent production of IFN-γ in response to IL-12 [43] [44] [45] . We therefore tested the effects of a specific p38 MAPK inhibitor on the production of IFN-γ by PBMCs stimulated with IL-12 and/or IL-18. Using PBMCs obtained from healthy control subjects, we confirmed that the p38 MAPK inhibitor (SB203580) inhibited, in a dose-dependent manner, production of IFN-γ in response to IL-12 and IL-18; the control reagent (SB202474) had no major effect ( Figure 7A) . Similarly, the p38 MAPK inhibitor specifically inhibited (by ~90%) production of IFN-γ induced by IL-12 and IL-18 stimulation of PBMCs obtained from patients after autologous stem cell transplantation ( Figure 7B ).
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Discussion
Production of IFN-γ in vivo is required for the efficacy of IL-12-based immunotherapy in many preclinical tumor models 13, 14, 16, 46, 47 . IFN-γ production after vaccination has also been found to be critical for the efficacy of peptide, dendritic cell, and cytokine-transduced tumor cell vaccines 33, 48, 49 . 
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transplant, a similar degree of STAT4 deficiency was seen in PBMC samples obtained 5-6 months posttransplant (n = 4; data not shown). Thus, simply delaying immunotherapy until 6 months after stem cell transplantation is not likely to be a successful strategy for circumventing defective IFN-γ production.
Indeed, such a delay could potentially inhibit the efficacy of immunotherapy by allowing the tumor burden to increase.
The mechanisms underlying deficient STAT4 protein levels in post-transplant patient PBMCs have not been fully elucidated and will be the subject of future investigation. Inhibition of STAT4 gene expression, decrease in STAT4 mRNA stability, or accelerated degradation of STAT4 protein could contribute to STAT4 deficiency. The reduction in STAT4 protein levels (97%) was more profound than the reduction in STAT4 mRNA levels (69%). Although direct comparison of RNA and protein levels is not appropriate given the different methodologies used, enhanced STAT4 protein degradation as well as decreased STAT4 mRNA levels could be involved in post-transplantation STAT4 deficiency. The relative contributions of high-dose chemotherapy, pre-transplant conventional chemotherapy, and disease status (histologic subtype of lymphoma, tumor burden) to STAT4 deficiency also require further study. Our preliminary data indicate that varying degrees of STAT4 deficiency can be seen in lymphoma patient PBMCs obtained prior to autologous stem cell transplantation; however, the STAT4 deficiency pre-transplant is not as profound or consistent as that seen after autologous stem cell transplantation (unpublished data). In contrast, we did not observe decreased STAT4 protein levels in PBMCs obtained from 2 lymphoma patients who had not been treated with chemotherapy (unpublished data). One plausible hypothesis is that STAT4 deficiency is a consequence of cytotoxic chemotherapy, and that its severity is directly related to the duration or intensity of such chemotherapy. Further investigation is needed to test this hypothesis.
After stimulation in vitro with PMA and ionomycin, comparable IFN-γ levels were detected in the supernatants of post-transplant patient and control subject PBMCs. This indicates that post-transplant patient PBMCs are capable of producing normal levels of IFN-γ when sufficiently activated. We therefore wished to identify more physiologic and clinically feasible stimuli that could promote IFN-γ production after stem cell transplantation. We found that IL-12 and IL-18 in combination could partly reverse . IL-18 can also be given safely in biologically active doses to patients with advanced cancer 59, 60 . were incubated with or without IL-12 100 U/mL for 1 hour as indicated, lysed, resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted using antibodies specific for tyrosine phosphorylated STAT4, total STAT4, or GAPDH as indicated. Location of the specific band for total STAT4 is indicated by the arrow. The identity of the STAT4 band was confirmed as described in Methods. Results are representative of those seen with 6 control samples and 6 patient samples that were tested. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
